Loading...
Please wait, while we are loading the content...
Similar Documents
T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy
| Content Provider | MDPI |
|---|---|
| Author | Mak, Anselm |
| Copyright Year | 2022 |
| Description | The phenotypic and functional complexities of T cells engender complicated and often confusing concepts as to how T cells ignite, accelerate and brake the inflammatory processes involved in systemic lupus erythematosus (SLE), let alone the plasticity of T cells that takes place under different immunological contexts. Nevertheless, being one of the prime survival factors of T cells, interleukin (IL)-2 plays a potentially critical role in many immunological scenarios during the pathophysiological process of SLE. Here, the pathophysiology of lupus T cells and current, as well as ongoing, therapeutic approaches of SLE that involve low-dose IL-2 administration will be highlighted. The mechanisms of IL-2 deficiency in SLE pathophysiology, the effects of low-dose IL-2 on T cells and restoration of lupus manifestations in murine SLE models, as well as the efficacy and safety of clinical trials that evaluated low-dose IL-2-containing regimens in patients with SLE will be discussed. |
| Starting Page | 980 |
| e-ISSN | 20734409 |
| DOI | 10.3390/cells11060980 |
| Journal | Cells |
| Issue Number | 6 |
| Volume Number | 11 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-03-12 |
| Access Restriction | Open |
| Subject Keyword | Cells Immunology Sle Lupus T Cell Regulatory Interleukin-2 |
| Content Type | Text |
| Resource Type | Article |
